首页> 外文期刊>BMC Cancer >High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy
【24h】

High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy

机译:高档术后并发症会影响患有细胞功能性手术和高温腹膜内化疗治疗结肠直肠癌腹膜转移患者的存活结果

获取原文
           

摘要

This study aimed to evaluate the impact of postoperative complications on long-term survival in patients with peritoneal metastasis (PM) arising from colorectal cancer (CRC) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients with PM arising from CRC treated with CRS and HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. High-grade complications that occurred within 30?days were defined as grade 3 to 4 events according to the Common Terminology Criteria for Adverse Events (CTCAE) classification. Univariate and multivariable Cox regression models for overall survival were created. Predictors of high-grade postoperative complications were evaluated with univariate and multivariate logistic regression analyses. In all, 86 consecutive cases were included in this study. Forty-one patients (47.7%) developed postoperative complications, while 22 patients (25.6%) experienced high-grade complications. No mortality occurred during the postoperative period. The median survival of all patients was 25?months, and the estimated 3-year overall survival (OS) rate was 35.0%. In the multivariable Cox regression analysis, a high peritoneal carcinomatosis index (PCI) score (HR, 1.07, 95% CI, 1.01–1.14; P=0.015) and grade 3–4 postoperative complications (HR, 1.86, 95% CI, 1.22–3.51; P=0.044) correlated with worse overall survival. High estimated blood loss (OR, 1.01, 95% CI, 1.01–1.02; P?0.001) was identified as an independent risk factor for developing high-grade complications. Careful patient selection, high levels of technical skill and improved perioperative management are crucial to ensure patient survival benefits after CRS HIPEC.
机译:本研究旨在评估术后并发症对腹膜转移(PM)患者长期存活的影响(CRC)治疗(CRS)和高温腹膜化疗(HIPEC)治疗的结肠直肠癌(CRC)。 2017年6月至2019年6月,在中国国家癌症中心和Huanxing Cancer医院系统地审查了患有CRS和HIPEC的CRC的患者。30?天内发生的高档并发症,定义为3至4级事件对不良事件(CTCAE)分类的共同术语标准。创建了整体存活的单变量和多变量的Cox回归模型。通过单变量和多变量的物流回归分析评估了高档术后并发症的预测因素。总之,这项研究总结了86例。第四十二名患者(47.7%)开发出术后并发症,而22例患者(25.6%)经历了高档并发症。术后期间没有死亡率。所有患者的中位数存活率为25岁,数月,估计的3年总生存率(OS)率为35.0%。在多变量的Cox回归分析中,高腹膜癌症指数(PCI)得分(HR,1.07,95%CI,1.01-1.14; P = 0.015)和3-4级术后并发症(HR,1.86,95%CI,1.22 -3.51; p = 0.044)与总体存活率更差相关。高估计血液损失(或1.01,95%CI,1.01-1.02; p&Δ0.001)被鉴定为开发高档并发症的独立危险因素。仔细的患者选择,高水平的技术技能和改善的围手术期管理是至关重要的,以确保CRS Hipec后患者存活效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号